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Objective: Increases in resting-state heart rate and decreases in its variability are 
associated with substantial morbidity and mortality, yet contradictory findings have 
been reported for the effects of the mood and anxiety disorders, and antidepressants. 
Here we apply a relatively novel method – propensity score weighting – to control for 
a host of potential confounds in a large cohort from Brazil. Method: A total of 15,105 
participants were recruited in the Brazilian Longitudinal Study of Adult Health (ELSA-
Brasil) between 2008 and 2010. Mood and anxiety disorders were determined using 
the Portuguese version of the Clinical Interview Schedule-Revised. Heart rate and its 
variability were extracted from 10-minute resting-state electrocardiogram recordings. 
Results: Use of antidepressant medications was associated with increases in heart 
rate and decreases in its variability. Effects were most pronounced for the tricyclics 
(Cohen’s d’s 0.72 – 0.81), followed by serotonin and noradrenaline reuptake 
inhibitors (serotonin and noradrenaline reuptake inhibitors; Cohen’s d’s 0.42 – 0.95) 
and other antidepressants (Cohen’s d’s 0.37 – 0.40), relative to those not on any 
antidepressants. Only participants with generalised anxiety disorder (GAD) showed 
robust, though small, increases in heart rate and decreases in its variability after 
propensity score weighting. Conclusions: Findings may, in part, underpin 
epidemiological findings of increased risk for cardiovascular morbidity and mortality. 
It is important to note that many factors adversely impacting on cardiac activity were 
controlled in this study, highlighting the importance of cardiovascular risk reduction 
strategies. Future studies are needed to examine whether, how and when such 
effects contribute to morbidity and mortality. 
 
Keywords: resting-state, heart rate variability; HRV; heart rate; mood and anxiety 
disorders; generalised anxiety disorder; antidepressants; tricyclics; serotonin and 
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noradrenaline reuptake inhibitors; SNRIs; selective serotonin reuptake inhibitors; 
SSRIs   
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Introduction 
Heart rate and its variability are determined by a variety of physiological factors, the 
most prominent of which is the autonomic system. In the resting state, the heart is 
under tonic inhibitory control by the parasympathetic (vagal) nervous system (1). The 
parasympathetic and sympathetic nervous systems are typically conceptualised as 
two opposing components, however, recent thinking indicates that vagal activity may 
be withdrawn without a corresponding increase in sympathetic nervous system 
activity (2). This metabolically conservative response during challenge may mirror 
autonomic dysregulation in psychiatric illness during the resting state. It is in this 
regard that we refer to resting state heart rate and its variability as surrogate markers 
of vagally-mediated, cardiac activity. It is important to acknowledge however, that 
measures of heart rate variability and the high frequency component in particular are 
more pure indicators of vagal activity (3) than heart rate, which may include 
sympathetic input. The present paper examines the impact of depression, anxiety, 
comorbidity and antidepressants on resting-state heart rate and its variability, 
measures we now denote as vagal activity, for brevity. 
 
Vagal activity plays an important role in mental and physical wellbeing (see 4 for 
review). Increases in vagal activity are associated with positive emotions, social 
connectedness and longevity. By contrast, decreases in vagal activity are associated 
with depression, anxiety, cardiovascular disease and mortality, findings that may be 
attributable to the downstream effects of a poorly functioning cholinergic anti-
inflammatory reflex. Other mechanisms including chronically elevated activity in the 
sympathetic nervous system are also involved in the pathway from emotion to 
morbidity. However, we suggest that vagal activity may provide a unique, structural 
link from day-to-day emotion experience to morbidity and mortality from a host of 
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conditions. In this regard, within-subject, phasic changes in vagal activity reflect a 
normal response to environmental challenge, while between-subject, resting state, 
tonic differences in vagal activity predict future mortality. In this regard, an early, 
seminal study on the effects of decreased heart rate variability in participants 
following acute myocardial infarction – as measured by the standard deviation of all 
normal RR intervals in 24-hour continuous electrocardiogram recordings from Holter 
monitors – (5) reported a five-fold increased relative risk of mortality. 
 
We and others have demonstrated that vagal activity is reduced in the mood and 
anxiety disorders (see 4 for review). In one of the first studies on this topic more than 
two decades ago (6), depressed patients with coronary artery disease were found to 
have increased heart rate, relative to non-depressed patients with coronary artery 
disease, independent of age, smoking and beta blocker medication. Depressed 
patients also displayed reduced heart rate variability, albeit at trend levels. This study 
was also based on data extracted from 24-hour ambulatory electrocardiogram 
recordings. Reliable and valid measures of heart rate and its variability may also be 
obtained from shorter recordings under standardised and controlled conditions (7). 
Using short-term electrocardiogram recordings in another early study (8), we 
reported that patients with generalised anxiety disorder display lower high frequency 
heart rate variability. High frequency heart rate variability, in particular, is mediated 
solely by changing levels of vagal activity (3). We concluded that generalised anxiety 
disorder and its cardinal feature (worry) are associated with reduced vagal activity. 
More recently, we demonstrated that patients with comorbid major depressive 
disorder (hereby denoted as depression) and generalised anxiety disorder (see 4 for 
review; 9) display the most robust reductions in resting-state vagal activity. Our 
explanation for these findings is that chronic worry and hypervigilance to threat may 
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underpin chronic withdrawal of vagal activity that may subsequently lead to 
increased morbidity and mortality.  
 
Recent debate has focused on whether mental disorders such as depression and 
anxiety are associated with reductions in vagal activity (see 4 for review) or whether 
these findings are driven by antidepressant medications (10; 11). However, studies 
have seldom used appropriate measures to adequately control for the effects of 
these variables on vagal activity. Inappropriate control of confounding factors may 
lead to a phenomenon known as the ‘reversal paradox’, in which “the association 
between two variables may be reversed, diminished or enhanced when another 
variable is statistically controlled” (12). Here we control for confounding factors 
through propensity score weighting using a generalised boosted modelling technique 
(13).  
 
This relatively novel method has several advantages over traditional regression-
based techniques including 1) application of flexible machine learning algorithms 
yielding well-calibrated estimates, 2) capture of complex and nonlinear relationships 
between groups and covariates without overfitting, 3) reduced bias by estimating the 
propensity score without reference to the outcome variable, and 4) the opportunity to 
analyse observational data to mimic the advantages of a randomised controlled trial 
design. This methodological approach provides an alternative to multiple regression 
that is more interpretable and less prone to violation of model assumptions (14). We 
apply this technique on a large sample of participants recruited for the Brazilian 
Longitudinal Study of Adult Health (ELSA-Brasil) (15).  
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ELSA-Brasil is the first large multi-centre cohort study of adult health conducted in 
Brazil. It is an ongoing cohort study designed to investigate the relationship between 
cardiovascular diseases and diabetes, their social determinants and risk factors. In 
this regard, vagal activity is an important consideration (see 4 for a review), and 
cross-sectional analysis of the ELSA-Brasil cohort at baseline will provide an 
important foundation for future longitudinal analyses on this cohort. Consistent with 
our prior studies on relatively smaller samples (9; 16; 17), we hypothesised that 
individuals diagnosed with the mood and anxiety disorders would display reductions 
in vagal activity, while use of antidepressants would be associated with further 
reductions, a finding that would be most apparent in users of tricyclic medications.  
 
Method 
Participants 
A total of 15,105 civil servants aged 35 to 74 were recruited for the first wave of 
ELSA-Brasil (15) between August 2008 and December 2010 at 6 different sites in 
Brazil. Exclusion criteria comprised current or recent pregnancy (within 4 months of 
first interview), intention to quit working at the institution in the near future, severe 
cognitive or communication impairment, and if retired, residence outside of a study 
centre’s metropolitan area. The study design and sampling procedures of ELSA-
Brasil have been reported previously (15).1  
 
Procedures 
                                            
1 See also vol.47, supl.2 of Rev. Saúde Pública (available at: http://goo.gl/ai2i1z). 
This supplement is dedicated to methodological aspects of the ELSA-Brasil study 
and includes articles in English.  
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Data were collected from participants in two phases: the first, lasting approximately 1 
hour, included collection of informed consent and an initial interview at the 
participant’s job site, while the second, lasting approximately 6 hours, was conducted 
in a study clinic and involved additional interviews, clinical exams and collection of 
blood and urine samples. Participants were asked to abstain from caffeine, alcohol 
and physical activity 12 hours prior to electrocardiogram assessment. A 
comprehensive set of examinations and measurements including electrocardiogram 
assessment were carried out. These procedures are described in more detail below 
(see also 15).  
 
Psychiatric Evaluation 
Mental disorders were determined by trained interviewers using the Portuguese 
version (18) of the Clinical Interview Schedule-Revised (CIS-R) (19). This is a 
structured interview used for diagnosis of current, common, non-psychotic 
psychiatric conditions in the community. The following categories were determined 
according to the 10th revision of the International Statistical Classification of 
Diseases and Related Health Problems: depression (F32.xx), agoraphobia (F40.0), 
social phobia (F40.1), specific phobia (F40.2), generalised anxiety disorder (F41.1), 
panic disorder (F41.0) and social anxiety disorder (F42). These diagnostic groupings 
were then reduced to five categories: depression, generalised anxiety disorder, all 
phobias, panic disorder, and a comorbid group comprised of participants with 
depression and any anxiety disorder.  
 
Electrocardiogram Assessment 
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Ten-minute, resting-state electrocardiogram was recorded from participants during 
spontaneous breathing without task demands, in the supine position. The 
electrocardiogram was always collected in the morning (8:00 to 12:00h) in a 
temperature-controlled room (21-24°C) and was sampled at 250 Hz with a digital 
electrocardiograph (Micromed, Brazil), consistent with international standards for the 
collection of heart rate variability (7). Wincardio (4.4a) software generated the R-R 
interval series from a selected lead (D2), associated with higher R-wave amplitude. 
We have described the artefact detection and spectral analytic techniques previously 
(20). Briefly, the R–R series was automatically pre-processed to remove ectopic 
beats and artefact, and linear interpolation was employed to replace any removed 
beats. Power spectral analysis was carried out by autoregressive modelling, 
estimated by the Yule Walker method, using the recursive algorithm of Levinson-
Durbin. Measures of heart rate and its variability including the root mean square of 
successive squared differences, and high frequency were then extracted. The high 
frequency (0.15–0.40 Hz) component was estimated and expressed in absolute units. 
Measures of heart rate variability were then log-transformed as a normalisation 
strategy.  
Covariates 
A host of covariates considered to impact on vagal activity were used in propensity-
score matching. Sociodemographic information included age and sex. Behavioural 
and lifestyle characteristics included smoking status (past or current versus never), 
physical activity (measured with the International Physical Activity Questionnaire and 
categorised according to low activity versus moderate or high activity as determined 
using scoring guidelines: http://www.ipaq.ki.se/scoring.pdf) and body mass index 
(weight in kilograms divided by height in meters squared). Health information 
included hypertension, diabetes mellitus, dyslipidemia, myocardial infarction and 
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coronary revascularisation. Hypertension was defined as systolic blood pressure 
≥140 mm Hg, or diastolic blood pressure ≥ 90mm Hg, or use of antihypertensive 
medications. Diabetes was defined as self-reported or fasting blood glucose ≥ 
126mg/dL or 2-hour oral glucose tolerance test ≥ 200mg/dL or glycated 
haemoglobin ≥ 6.5%. Dyslipidemia was defined as LDL-cholesterol ≥ 130mg/dL or 
use of lipid lowering medication. Blood samples were collected following a 12-hour 
overnight fast. Medication use for hypertension, diabetes, and lipid reduction, as well 
as antidepressants were identified on the basis of pill bottle review. Analysis on the 
mood and anxiety disorders also included CIS-R total score to control for disorder 
severity. 
 
Statistical analysis 
Statistical analysis was conducted using IBM SPSS Statistics Version 21 and the R-
statistical environment (version 3.0.1). Regressions weighted by propensity scores 
were carried out using the ‘twang’ and ‘survey’ packages in the R statistical 
environment. Both R and the two packages are freely available, and details on how 
to implement procedures have been described previously (13). Two main analyses 
were conducted. The first, involved comparison of controls, depression, phobias, 
panic disorder, generalised anxiety disorder and participants with comorbid 
depression and any anxiety disorder on measures of vagal activity (heart rate, root 
mean square of successive differences and high frequency). The second, compared 
users of selective serotonin reuptake inhibitors, serotonin and noradrenaline 
reuptake inhibitors, tricyclic and other antidepressants on these same measures. 
Effective sample sizes (reported as ‘n’) were obtained after propensity score 
weighting; these reflect numbers of participants with similar features on covariates in 
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each of the groups. Effective sample sizes capture the adverse impact of increased 
variance on precision and power (13). Sensitivity analyses were conducted using 
propensity score matching. While weighting involves covariance-adjusted, 
regression-based modelling in which propensity scores are used as a covariate, 
matching involves selecting control participants to match comparison groups on 
propensity scores. Here, propensity score matching was carried using the ‘MatchIt’ 
package in the R-statistical environment using one-to-one, exact matching, which 
paired each participant of the comparison group with a participant from the control 
group based on the propensity score. IBM SPSS Statistics software was then used 
to conduct between-group t-tests on matched samples.  
 
Results 
Participant Characteristics  
Participant characteristics before and after propensity score weighting are presented 
in supplementary tables. Supplementary Table 1 displays characteristics for the 
mood and anxiety disorder groupings. Supplementary Table 2 displays 
characteristics for each of the antidepressant groupings.  
Impact of Disorder on Vagal Activity  
After propensity-score weighting, effective sample sizes were as follows: controls, 
n=10,346; depression, n=98; phobias, n=121; panic disorder, n=43; generalised 
anxiety disorder, n=1,183; and comorbid, n=311. Average heart rate was slightly 
increased in participants with generalised anxiety disorder relative to controls, a 
finding at trend levels, associated with a small effect size [M=67.30 versus 66.79, 
p=0.086, d=0.053]. No other groups differed from controls. Sensitivity analysis using 
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propensity-score matching revealed similar, trend-level findings for generalised 
anxiety disorder (n=1249) relative to controls (n=1236) [M=67.23 versus 67.90, 
p=0.065, d=0.074]. Analysis on heart rate variability revealed significant effects for 
both measures after propensity-score weighting; root mean square of successive 
differences was decreased in generalised anxiety disorder relative to controls 
[M=3.17 versus 3.21, p=0.015, d=0.075] as was high frequency [M=5.23 versus 5.32, 
p=0.033, d=0.066]. Again, no other groups differed from controls. Again, sensitivity 
analysis using propensity-score matching revealed similar findings for generalised 
anxiety disorder relative to controls [root mean square of successive differences: 
M=3.18 versus 3.25, p=0.004, d=0.116; high frequency: M=5.29 versus 5.42, 
p=0.005, d=0.113]. 
 
Impact of Antidepressants on Vagal Activity  
After propensity-score weighting, effective sample sizes were as follows: participants 
not on antidepressants, n=14,069; selective serotonin reuptake inhibitors, n=356; 
serotonin and noradrenaline reuptake inhibitors, n=52; tricyclic antidepressants, 
n=84; and other antidepressants, n=75. Tricyclic antidepressants (M=73.94, p<0.001, 
d=0.721), other antidepressants (M=71.00, p=0.001, d=0.380) and serotonin and 
noradrenaline reuptake inhibitors (M=70.55, p=0.003, d=0.420) were associated with 
an increase in heart rate relative to those not on antidepressants (M=66.87), while 
selective serotonin reuptake inhibitors were associated with a small decrease 
(M=65.40, p=0.003, d=0.161). In addition, all antidepressants were associated with a 
decrease in heart rate variability [root mean square of successive differences, 
tricyclic antidepressants: M=2.71, p<0.001, d=0.810, serotonin and noradrenaline 
reuptake inhibitors: M=2.79, p<0.001, d=0.952, Other: M=2.95, p<0.001, d=0.402; 
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selective serotonin reuptake inhibitors: M=3.08, p<0.001, d=0.280; high frequency, 
tricyclic antidepressants: M=4.26, p<0.001, d=0.730, serotonin and noradrenaline 
reuptake inhibitors: M=4.48, p<0.001, d=0.789, Other: M=4.82, p=0.001, d=0.367, 
selective serotonin reuptake inhibitors: M=5.05, p<0.001, d=0.254] relative to those 
not on antidepressants [root mean square of successive differences: M=3.23; high 
frequency: M=5.36]. These findings were all replicated in sensitivity analysis using 
propensity-score matching (results not shown).   
 
Discussion 
The most striking effects from our study relate to the use of antidepressant 
medications; tricyclic, serotonin and noradrenaline reuptake inhibitors and other 
antidepressants were associated with moderate to large adverse effects. With 
respect to the impact of mood and anxiety disorders – an issue that has attracted the 
most debate – findings demonstrate that only generalised anxiety disorder is 
associated with a reduction in vagal activity after controlling for a host of clinical 
covariates including biomarkers of metabolic and cardiovascular risk. The effects of 
generalised anxiety disorder on vagal activity were statistically significant and robust, 
although effect sizes were small. This is an important finding as other researchers 
have recently argued that it is the antidepressant medication, rather than the 
disorder per se, that adversely impacts on vagal activity (10; 11). While it is notable 
that participants with comorbid depression and anxiety disorders did not display 
reductions in vagal activity, it is important to remind readers that many of the factors 
that adversely affect vagal activity were controlled in this study. 
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The mood and anxiety disorders raise metabolic and cardiovascular risk (21), 
emphasising the need for comprehensive cardiovascular risk reduction strategies in 
all patients with these disorders to minimise subsequent morbidity and mortality. In 
the present study, we show that only generalised anxiety disorder without 
comorbidity is associated with reductions in vagal activity. These findings highlight 
the independent, adverse effects of generalised anxiety disorder without comorbidity 
on vagal activity. It is important to note here however, that generalised anxiety 
disorder and depression are linked to each other sequentially such that each 
disorder increases the likelihood of developing the other disorder over time (22). 
Longitudinal follow-up of our participants will provide important data to further 
examine the relationship between depression and generalised anxiety disorder over 
time, and their effects on vagal activity. In line with our prior studies on generalised 
anxiety disorder (8; 9), we suggest that the cardinal features of this disorder, 
including chronic worry and hypervigilance to threat independently contribute to long-
term reductions in vagal activity and subsequent increases in morbidity and mortality.  
 
Our study is now placed in the context of prior studies, which have reported 
contradictory findings leading to significant debate and discussion. In 2007, 
Rottenberg (23) reported findings from a meta-analysis indicating that depression 
adversely impacted on vagal activity, a finding associated with a small-to-medium 
effect size. He also suggested that low heart rate variability may be a consequence 
of comorbid anxiety, rather than depression per se. In 2008 and 2009, Licht and 
colleagues reported that although heart rate variability is reduced in patients with 
depression (24) and those with anxiety disorders (25), these reductions are driven by 
antidepressant medications. These findings contrasted with smaller studies that had 
reported adverse effects of the mood and anxiety disorders leading to the publication 
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of our meta-analysis in 2010 (16). We reported that heart rate variability was reduced 
in depressed, unmedicated patients relative to controls, a finding associated with a 
large effect size when focusing on non-linear measures of heart rate variability. 
Recent years have witnessed increasing calls for independent replication of 
published findings in science (26; 27). Consistent with this goal, we have examined 
the impacts of the mental disorders and antidepressants on vagal activity using a 
variety of approaches. In addition to meta-analysis, we have replicated reductions in 
the mood and anxiety disorders in multiple independent cohorts of patients (9; 17; 
28). In the largest independent cohort to date, we now report that after controlling for 
multiple confounding variables, generalised anxiety disorder displays robust, albeit 
small, reductions in vagal activity. It is possible that the lack of findings for MDD 
relate to disorder heterogeneity. For example, specific patient characteristics (e.g. 
melancholia) may be associated with more robust effects on vagal activity. 
 
We suggest here that the effects we observed for the tricyclics and serotonin and 
noradrenaline reuptake inhibitors in particular, may underpin previously reported 
increases in risk for cardiovascular morbidity and mortality (29; 30). There is strong 
evidence for a continuous increase in risk for cardiovascular and all-cause mortality 
in men and women with a resting heart rate above 60 beats/minute, regardless of 
whether individuals have a history of cardiovascular disease (31). In the present 
study we show that tricyclic antidepressants are associated with an average resting 
heart rate of ~74 beats per minute (BPM), while serotonin and noradrenaline 
reuptake inhibitors and other antidepressants are associated with an average resting 
heart rate of approximately ~71 BPM, relative to non-users of antidepressants (~67 
BPM). In light of the increasing concerns over the impact of antidepressant 
medications (10; 29; 30), we recently investigated the moderating effects of physical 
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activity on the impact of the selective serotonin reuptake inhibitors, escitalopram, on 
cardiac stress responses (32). We found that participants who engaged in exercise 
at least 3 times per week display a more resilient vagal response to stress, relative to 
irregular exercisers, a finding associated with a moderate effect size. We also 
observed that acute escitalopram had a similar impact on irregular exercisers during 
stress. The moderating effects of regular exercise in long-term users of 
antidepressant medications needs to be examined in future research. In the present 
study, the selective serotonin reuptake inhibitors were associated with a decrease in 
heart rate as well as its variability. It is particularly interesting that these findings 
have been reported previously for this class of medication (10); findings that were 
interpreted as both a decrease in sympathetic activity and parallel decreases in net 
cardiac vagal effects. 
 
While our study has important strengths – particularly the application of propensity 
score weighting on a large, independent cohort of participants – a number of 
limitations should also be noted. Firstly, the reliability of short-term measurements of 
heart rate variability has been questioned (33). However, we have demonstrated that 
the protocol on which the present study is based shows good reproducibility (see 34). 
Secondly, we acknowledge that respiration rate may influence estimates of heart 
rate and its variability. While we did not collect data on respiration rate in our 
participants, the question of whether or not respiration rate should be controlled 
remains a divisive issue in the field of psychophysiology. Researchers have even 
cautioned against experimentally controlling for respiration as this may confound the 
visceral-medullary feedback system and shift respiratory parameters (2). Also, the 
root mean square of successive differences, unlike frequency-based measures, may 
actually be more robust to changes in breathing patterns (35). In the present study, 
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key findings were obtained across both measures of heart rate variability highlighting 
the robustness of findings. Finally, it should be noted that although we controlled for 
a variety of important covariates, there are likely other factors that we did not 
measure or include in our models that may have impacted on findings. Thus, there 
remains the potential for residual confounding factors in our study.  
 
In summary, the present study provides much needed evidence for the impact of the 
mood and anxiety disorders, and antidepressants on resting-state vagal activity, after 
controlling for a large number of confounding factors. Future studies employing a 
randomized-controlled design will provide further, important evidence for the impact 
of specific antidepressants on vagal activity. Further research is also needed to 
determine whether certain clinical characteristics and their amelioration moderate 
observed findings. It is possible for instance, that specific subtypes of depression 
(e.g. melancholia) or symptoms of a depressive episode or the anxiety disorders (e.g. 
somatic symptoms) have more robust effects on vagal activity. There is also a need 
for future research to determine how and when reduced vagal activity leads to 
morbidity and mortality from a host of conditions.  
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Fig 1: Key findings associated with the impact of antidepressants on heart rate and 
its variability (including root mean square of successive squared differences 
and high frequency after log-transformation) following propensity score 
weighting. Group means and 95% confidence intervals corresponding to the 
propensity score weighted regression are displayed. These were extracted 
using the ‘svyby’ function.  
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